Heron Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The meeting saw the election of seven directors, approval of all six proposals including auditor ratification, executive compensation, and amendments to equity and stock purchase plans. No questions were raised by stockholders during the session.
-
Q1 2026 net sales were $34.7M, impacted by severe weather and seasonal headwinds, but March sales rebounded above $15M. Acute care and oncology portfolios showed strong year-over-year growth, and full-year guidance for $173–$183M in sales and $10–$20M adjusted EBITDA was reaffirmed.
Fiscal Year 2025
-
Delivered $155M in 2025 net revenues and $14.7M adjusted EBITDA, exceeding guidance. Acute care products ZYNRELEF and APONVIE drove strong growth, while oncology remained stable despite SUSTOL's decline. 2026 guidance targets $173M–$183M sales and $10M–$20M EBITDA.
-
Q3 2025 saw strong revenue growth in acute care, with ZYNRELEF and APONVIE sales surging year-over-year. Gross margin was impacted by a one-time write-off, but adjusted EBITDA turned positive. Guidance for 2025 was reaffirmed, and new reimbursement and product initiatives are expected to drive further growth.
-
Q2 2025 saw strong revenue and margin growth, improved profitability, and successful refinancing. ZYNRELEF and APONVIE posted robust demand, with new salesforce strategies and a permanent J code set to drive future growth.
-
Q1 2025 saw $39M in revenue, $6.2M adjusted EBITDA, and $2.6M net income, with strong growth in APONVIE and ZYNRELEF. Revised EBITDA guidance is now $4M–$12M, and new account onboarding plus partnerships are expected to drive further gains in the second half of the year.
Fiscal Year 2024
-
Profitability was achieved in Q4 and for the full year 2024, with net revenues up 14% year-over-year and gross margin rising to 73%. ZYNRELEF and APONVIE drove strong growth, while guidance for 2025 anticipates continued expansion amid competitive pressures and higher operating expenses.
-
Q3 2024 featured strong revenue growth, improved gross margins, and narrowed financial guidance. FDA approval of VAN and inclusion in the NOPAIN Act are set to boost Zynrelef, while the CrossLink partnership and One Heron initiative are driving portfolio momentum.
-
Revenue grew 15% year-over-year with gross margin rising to 73% and operating expenses down over $36 million. ZYNRELEF and APONVIE showed strong growth, and the NOPAIN Act plus CrossLink partnership are set to drive further gains in 2025.